Skip to main content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SAVOIR trial

Toni Choueiri discusses how the phase 3 SAVOIR trial of savolitinib in MET-driven papillary renal cell carcinoma could inform future research despite being terminated early (4:23).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits